Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars OBRoncology 812 подписчиков Скачать
Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings Скачать
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape Скачать
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care Скачать
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care Скачать
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings Скачать
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices Скачать
Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology Скачать
Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence Скачать
Jonathan E. Levitt, Esq., on the experience of hem/onc groups unable to enter into a PBM network Скачать
Jonathan E. Levitt, Esq., offers opinion on PBM consolidation & the changing dynamics of cancer care Скачать
Jonathan E. Levitt, Esq., considers how PBM behaviors are changing as a result of the pandemic Скачать
Sara Riordan, MS, CGC, on the role of genetic counselors as part of a multidisciplinary cancer team Скачать
Sara Riordan, MS, CGC, on how genetic signature & biomarker tests are used in cancer management Скачать
Lalan S. Wilfong, MD, discusses key takeaways from the 2021 Virtual Community Oncology Conference Скачать
Lalan S. Wilfong, MD, regarding the impact of geographic location on the delivery of cancer care Скачать
Lalan S. Wilfong, MD, offers opinion on the key success factors for new payment reform models Скачать
Mary J. Fidler, MD, provides opinion on the role of nivolumab + ipilimumab in the treatment of NSCLC Скачать
Mary J. Fidler, MD, regarding the role of trilaciclib as a supportive care agent for SCLC patients Скачать
Mary J. Fidler, MD, on combination lurbinectedin & checkpoint inhibitors in the treatment of SCLC Скачать
Sibel Blau, MD, regarding the greatest challenges in treating cancer patients during COVID-19 Скачать
Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer Скачать
Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC Скачать
Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer Скачать
Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC Скачать
Matthew Galsky, MD, tells us about the design and outcomes of the EV-301 trial from ASCO GU '21 Скачать
Sumanta K. Pal, MD, offers a message to patients regarding clinical progress in kidney cancer Скачать
Sumanta K. Pal, MD, elaborates on the design and outcomes of the PAPMET trial from ASCO GU 2021 Скачать
Robert J. Motzer, MD, discusses the side effect profiles of the combinations in the CLEAR trial Скачать
Robert J. Motzer, MD, offers opinion on whether findings from the CLEAR trial are practice-changing Скачать
David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCC Скачать
Jeanny B. Aragon-Ching, MD, FACP, shares the design and outcomes of the EV-301 clinical trial Скачать
Tanya Dorff, MD, on how checkpoint inhibitors are being incorporated into mCRPC treatment algorithms Скачать
Tanya Dorff, MD, on the role of chemotherapy in mCRPC patients who have failed prior therapies Скачать
Elisabeth Heath, MD, FACP, explains the design and outcomes of the ACIS study from ASCO GU 2021 Скачать
Elisabeth Heath, MD, FACP, shares updated results of the TITAN clinical trial from ASCO GU 2021 Скачать
Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC Скачать
Daniel M. Geynisman, MD, considers implications for patients as a result of the RETAIN BLADDER trial Скачать
Daniel M. Geynisman, MD, provides an overview of the RETAIN BLADDER presented at ASCO GU 2021 Скачать
Thomas Powles, MD, PhD, FCRP, offers opinion on whether the results of EV-301 are practice-changing Скачать
Thomas Powles, MD, PhD, FCRP, regarding the EV-301 Phase III clinical study from ASCO GU 2021 Скачать
Thomas Powles, MD, PhD, FCRP, tell us about the novel antibody-drug conjugate enfortumab vedotin Скачать
Arlene Siefker-Radtke, MD, regarding the EV-201 Cohort 2 study & clinical implications for patients Скачать
Arlene Siefker-Radtke, MD, discusses key takeaways from the EV-301 study in urothelial cancer Скачать
Kim N. Chi, MD, speculates on the future role of apalutamide in the treatment of prostate cancer Скачать
Kim N. Chi, MD, considers the impact of the crossover design in the analysis of the TITAN study Скачать
Kim N. Chi, MD, regarding key highlights from the final analysis of the Phase III TITAN study Скачать
Arlene Siefker-Radtke, MD, on the management of treatment-emergent AEs & the use of FGFR inhibitors Скачать
Arlene Siefker-Radtke, MD, discusses some of the antibody drug conjugates currently in development Скачать
Arlene Siefker-Radtke, MD, speculates on the role of antibody drug conjugates in the treatment of UC Скачать
David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing Скачать
Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer Скачать
Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021 Скачать
Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021 Скачать
Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC Скачать
Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC Скачать
Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150 Скачать
Namrata Vijayvergia, MD, offers opinion on the use of FGFR inhibitors in the treatment of CCA Скачать
Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021 Скачать
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation Скачать
Zev Wainberg, MD, regarding bemarituzumab as a single agent in the treatment of gastric cancer Скачать
Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer Скачать
Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial Скачать
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types Скачать
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial Скачать
Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer Скачать
Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin Скачать
Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020 Скачать
Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer Скачать
Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer Скачать
Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020 Скачать
Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors Скачать
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020 Скачать
Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE Скачать
Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer Скачать
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer Скачать
Priya Rastogi, MD, shares the design and outcomes of the monarchE clinical trial from SABCS 2020 Скачать
Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020 Скачать
Hope Rugo, MD, provides perspective on the clinical progress of CDK 4/6 inhibitors in breast cancer Скачать
Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020 Скачать
Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat Скачать
Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients Скачать
Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy Скачать
Erika Hamilton, MD, on promising treatment options in the management of HER2+ advanced breast cancer Скачать
Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment Скачать
Erika Hamilton, MD, provides perspective on the latest immunotherapy treatment trends in TNBC Скачать
Erika Hamilton, MD, discusses findings from the MARIO-3 clinical trial presented at the 2020 SABCS Скачать
David Sallman, MD, offers opinion on the most exciting clinical data in AML coming out of ASH 2020 Скачать
Mazyar Shadman, MD, on the investigation of 3rd-generation CAR T-cell therapies targeting CD20 Скачать
Frederick Locke, MD, summarizes outcomes from the ZUMA-1 clinical trial presented at ASH 2020 Скачать
David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia Скачать
Mazyar Shadman, MD, on patients with B-cell malignancies who are intolerant to 1st line ibrutinib Скачать
